Skip navigationEnd of navigation

Funding Opportunities

NewsNewslettersMeetings and EventsFunding Opportunities

NCI Research Specialist (Clinician Scientist) Award (R50 Clinical Trial Not Allowed)

The National Cancer Institute (NCI) invites applications for the Research Specialist Award (R50) for Clinician Scientists supporting NCI-funded clinical trials research. The Research Specialist Award is designed to encourage the development of stable research career opportunities for exceptional clinician scientists who want to continue to participate in the NCI clinical trials networks through leadership in the 1) development of national clinical trials, 2) implementation of NCI clinical trials in their institutions, and 3) national service to the NCI clinical trials networks through participation in the scientific review committees, monitoring committees and other activities, but not serve as principal investigators of research project grants. These clinician scientists are vital to sustaining the NCI-funded clinical trials enterprise. The Research Specialist Award is intended to provide salary support and sufficient autonomy so that individuals are not solely dependent on NCI grants held by others or other sources of support for cancer research career continuity.

Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research (U01 Clinical Trial Not Allowed)

Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) encourages the submission of applications that propose to advance research in cancer etiology and early detection biomarkers, utilizing the advantages of the unique biorepository resources of the NCI-sponsored Prostate, Lung, Colorectal, and Ovarian Cancer (PLCO) Screening Trial. The PLCO Biorepository offers high-quality, prospectively collected, serial pre-diagnostic blood samples from the PLCO screened arm participants, and a onetime collection of buccal cells from both the screened and the control arm participants. Available data associated with the biospecimens includes demographic, diet, lifestyle, smoking, screening results, and other clinical data. This FOA supports a wide range of cancer research including, but not limited to, biochemical and genetic analyses of cancer risk, as well as discovery and validation of early detection biomarkers. The proposed research project must involve use of PLCO biospecimens and may include other resources; additionally, it should also take advantage of the unique characteristics of the PLCO biospecimens. Research on non-cancer outcomes, especially those related to aging (e.g., Alzheimer.s, depression, hip fracture, osteoporosis and rheumatoid arthritis) may also be supported.

NCI Research Specialist (Clinician Scientist) Award (R50 Clinical Trial Not Allowed)

Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites applications for the Research Specialist Award in any area of NCI-funded clinical cancer research. This FOA is specifically for clinician scientists to continue to participate in the NCI clinical trials networks through leadership in the 1) development of national clinical trials, 2) implementation of NCI clinical trials in their institutions, and 3) national service to the NCI clinical trials networks through participation in the scientific review committees, monitoring committees, and other activities, but not serve as principal investigators of research project grants. These clinician scientists are vital to sustaining the NCI-funded clinical trials enterprise. The Research Specialist Award is intended to provide stable support for clinician scientists at their institutions for significant leadership and exceptional participation in the NCI-sponsored clinical trials networks that conduct cancer treatment, prevention and control, and care delivery clinical trials. NCI-sponsored clinical trials networks include but are not limited to the National Clinical Trials Network (NCTN), the NCI Community Oncology Research Program (NCORP), the Experimental Therapeutics Clinical Trials Network (ETCTN), and the Cancer Prevention Clinical Trials Network (CP-CTNet).

Notice of Special Interest: National Cancer Institute Administrative Supplement Opportunity for Strategies to Optimize Recruitment and Retention of Cancer Prevention and Symptom Management Clinical Trial Participants

The NCI is providing this opportunity for support of implementation and evaluation of promising clinical trial recruitment and retention strategies for cancer prevention, cancer control, and care delivery clinical trials, as well as quality-of-life studies embedded within treatment and imaging studies. The research solicited through this opportunity includes but is not limited to strategies that are directed toward NIH-designated U.S. health disparity populations, which include Blacks/African Americans, Hispanics/Latinos, American Indians/Alaska Natives, Asian Americans, Native Hawaiians and other Pacific Islanders, socioeconomically disadvantaged populations, underserved rural populations, and sexual and gender minorities as well as older adult populations. Research proposed for supplemental funding may include one or more strategies and may be applied to one or more studies or sites. Applications should include a prospective plan to evaluate the performance of the proposal as well as the effectiveness of the proposed strategy. Effectiveness of the strategy may include comparison with another strategy, participant surveys, staff satisfaction surveys or achievement of pre-specified recruitment and retention milestones.

Research Supplements to Promote Diversity in Health-Related Research (Admin Supp - Clinical Trial Not Allowed)

The NIH currently provides multiple opportunities to develop research careers and enhance participation for individuals from diverse backgrounds, including those from groups demonstrated to be underrepresented in the biomedical, behavioral, clinical and social sciences. Nevertheless, reports from the National Science Foundation and others provide strong evidence that underrepresentation remains an important problem that the entire research enterprise must actively address. This administrative supplement is designed to provide support for research experiences for individuals from diverse backgrounds throughout the continuum from high school to the faculty level.

NIH Planning Grant Program (R34)

The NIH Planning Grant Program (R34) provides support for the initial development of a clinical trial or research project.

Funding Archive